Medical Policy
Serum Biomarker Panel Testing for Systemic Lupus Erythematosus and Other Connective Tissue Diseases

Table of Contents
- Policy: Commercial
- Policy: Medicare
- Authorization Information
- Coding Information
- Description
- Policy History
- Information Pertaining to All Policies
- References

Policy Number: 702
BCBSA Reference Number: 2.04.123
NCD/LCD: NA

Related Policies
None

Policy
Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity
Medicare HMO BlueSM and Medicare PPO BlueSM Members

Serum biomarker panel testing with proprietary algorithms and/or index scores for the diagnosis of systemic lupus erythematosus and other connective tissue diseases is INVESTIGATIONAL.

Prior Authorization Information
Inpatient
- For services described in this policy, precertification/preauthorization IS REQUIRED for all products if the procedure is performed inpatient.

Outpatient
- For services described in this policy, see below for products where prior authorization might be required if the procedure is performed outpatient.

<table>
<thead>
<tr>
<th>Product</th>
<th>Coverage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commercial Managed Care (HMO and POS)</td>
<td>This is not a covered service.</td>
</tr>
<tr>
<td>Commercial PPO and Indemnity</td>
<td>This is not a covered service.</td>
</tr>
<tr>
<td>Medicare HMO BlueSM</td>
<td>This is not a covered service.</td>
</tr>
<tr>
<td>Medicare PPO BlueSM</td>
<td>This is not a covered service.</td>
</tr>
</tbody>
</table>

CPT Codes / HCPCS Codes / ICD Codes
Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.
Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

No specific CPT code

**Description**

**CONNECTIVE TISSUE DISEASES**

**Systemic Lupus Erythematosus**

Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disease (CTD) that affects approximately 1.5 million individuals in the United States.¹ It is one of several types of lupus, the others being cutaneous and drug-induced lupus. About 90% of lupus patients are women between the ages of 15 and 45 years. SLE causes inflammation and can affect any part of the body, most commonly the skin, heart, joints, lungs, blood vessels, liver, kidneys, and nervous system. Although generally not fatal, SLE can increase mortality, most commonly from cardiovascular disease due to accelerated atherosclerosis. SLE can also lead to kidney failure, which may reduce survival. The survival rate in the United States is approximately 95% at 5 years and 78% at 20 years.² The morbidity associated with SLE is substantial. Symptoms such as joint and muscle pain can impact quality of life and functional status. SLE also increases patients' risk of infection, cancer, avascular necrosis (bone death), and pregnancy complications (e.g., preeclampsia, preterm birth). The course of the disease is variable, and patients generally experience periods of mild-to-severe illness (called flares) and remission.

**Other Connective Tissue Diseases**

Several other CTDs may require a differential diagnosis from SLE (e.g., rheumatoid arthritis, Sjögren syndrome, antiphospholipid syndrome, and polymyositis).

Rheumatoid arthritis is a chronic inflammatory peripheral polyarthritis. Rheumatoid arthritis can lead to deformity through stretching of tendons and ligaments and destruction of joints through erosion of cartilage and bone. Rheumatoid arthritis can also affect the skin, eyes, lungs, heart, and blood vessels. Graves disease is an autoimmune disorder that leads to overactivity of the thyroid gland. The disease arises from thyroid-stimulating hormone receptor antibodies. It is the most common cause of hyperthyroidism. Blood tests may show raised thyroid-stimulating immunoglobulin antibodies.

Hashimoto disease, also known as chronic lymphocytic thyroiditis, is an autoimmune disorder and is the most common cause of hypothyroidism second to iodine insufficiency. It is characterized by an underactive thyroid gland and gradual thyroid failure. Diagnosis is confirmed with blood tests for thyroid stimulating hormone (T4) and antithyroid antibodies.

Sjögren syndrome is an autoimmune disorder characterized by dryness of the eyes and mouth due to diminished lacrimal and salivary gland function. Affected individuals may also have symptoms of fatigue, myalgia, and cognitive dysfunction, which may be difficult to distinguish clinically from fibromyalgia or medication side effects. Typical antibodies include antinuclear antibody (ANA), anti-Sjögren-syndromerelated antigen, anti-Sjögren syndrome type B, or rheumatoid factor.

Antiphospholipid syndrome is a systemic autoimmune disorder characterized by venous or arterial thrombosis and/or pregnancy morbidity. Antiphospholipid antibodies are directed against phospholipidbinding proteins.

Polymyositis and dermatomyositis are inflammatory myopathies characterized by muscle weakness and inflammation. Dermatomyositis may also have skin manifestations.

**Diagnosis**

Patients with SLE often present with nonspecific symptoms such as fever, fatigue, joint pain, and rash, which can make the disease difficult to diagnosis. In some patients, the diagnosis of SLE can be made with certainty (e.g., when there are typical symptoms of rash and joint symptoms, and laboratory testing shows a high-titer abnormal ANA in a pattern specific for SLE). However, in many other patients, the symptom patterns of SLE are less clear, and ANA testing is equivocal; as a result, cascade testing with...
additional serologic tests may be ordered. In addition, ANA testing alone can result in false positives due to low specificity.

**Classifications**
The diagnosis of SLE has been based on a combination of clinical symptoms and laboratory results. In 1997 the American College of Rheumatology (ACR) updated 1982 criteria for the classification of SLE.3,4

The ACR classification criteria are as follows:
1. Malar rash
2. Discoid rash
3. Photosensitivity
4. Mouth or nose ulcers (usually painless)
5. Arthritis (nonerosive) in 2 or more peripheral joints, along with tenderness, swelling, or effusion
6. Serositis: pleuritis or pericarditis
7. Renal disorder: excessive protein in the urine, or cellular casts in the urine
8. Neurologic disorder: seizures and/or psychosis, in the absence of offending drugs or known metabolic derangements
9. Hematologic disorders: hemolytic anemia, leukopenia, lymphopenia, or thrombocytopenia
10. Immuneologic disorder: antibodies to double-stranded DNA (anti-dsDNA), antibodies to Smith antigen (anti-Sm), positive antiphospholipid antibody, or false-positive serologic test for syphilis known to be positive for at least 6 months
11. ANA test in the absence of drugs known to induce it.

These criteria were originally developed for research, but they have been widely adopted in clinical care. Individuals who meet 4 or more of the 11 criteria are diagnosed with SLE. If a patient meets fewer than 4 of criteria, lupus can still be diagnosed by clinical judgment; it is recommended that a rheumatologist confirm the diagnosis.5 ANA testing is usually performed for patients who present with signs and symptoms involving two or more organ systems, and individuals who test positive are recommended for additional laboratory testing.6 Assessments of ACR’s 1982 criteria have reported sensitivities ranging from 78% to 95% and specificities ranging from 89% to 100%, with lower accuracy in patients with mild disease.6

In 2012, the Systemic Lupus International Collaborating Clinics (SLICC), an international group of researchers, developed revised criteria for diagnosing SLE.7 These criteria include more laboratory tests than the earlier ACR criteria, including elements of the complement system. Patients are classified as having SLE if they satisfy 4 or more of the 18 criteria below, including at least 1 clinical criterion and 1 immunologic criterion, or they have biopsy-confirmed nephritis compatible with SLE and with ANA or anti-dsDNA antibodies. In a sample of 690 patients, the SLICC criteria had a sensitivity of 97% and a specificity of 84% for diagnosing SLE, whereas the ACR criteria applied to the same sample had a sensitivity of 83% and a specificity of 96%. It is not clear how well-accepted the SLICC recommendations are in the practice setting. The SLICC criteria are outlined in Table 1.

**Table 1. Clinical and Immunologic Criteria**

<table>
<thead>
<tr>
<th>Clinical Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute cutaneous lupus (including but not limited to lupus malar rash)</td>
</tr>
<tr>
<td>Chronic cutaneous lupus (including but not limited to discoid rash)</td>
</tr>
<tr>
<td>Oral ulcers</td>
</tr>
<tr>
<td>Nonscarring alopecia in the absence of other causes</td>
</tr>
<tr>
<td>Synovitis involving ≥2 joints, characterized by swelling or effusion or and ≥30 min of morning stiffness</td>
</tr>
<tr>
<td>Serositis</td>
</tr>
<tr>
<td>Renal: excessive protein in the urine or cellular casts in the urine</td>
</tr>
<tr>
<td>Neurologic disorder: seizures, psychosis, mononeuritis complex, or peripheral, or cranial neuropathy</td>
</tr>
<tr>
<td>Seizures</td>
</tr>
</tbody>
</table>
• Hemolytic anemia
• Leukopenia or lymphopenia
• Thrombocytopenia

<table>
<thead>
<tr>
<th>Immunologic Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Antinuclear antibody above laboratory reference range</td>
</tr>
<tr>
<td>• Antibodies to double-stranded DNA above laboratory reference range</td>
</tr>
<tr>
<td>• Antibodies to Smith nuclear antigen</td>
</tr>
<tr>
<td>• Antiphospholipid antibody</td>
</tr>
<tr>
<td>• Low complement (low C3, low C4, or low CH150)</td>
</tr>
<tr>
<td>• Direct Coombs tests in the absence of hemolytic anemia</td>
</tr>
</tbody>
</table>

As previously noted, the SLICC classification system includes a wider range of laboratory tests than the ACR criteria. To date, the most common laboratory tests performed in the diagnosis of SLE are serum ANA, and, if positive, tests for anti-dsDNA and anti-Sm. ANA tests are highly sensitive (ie, with a high negative predictive value) but have low specificity and relatively low positive predictive value, particularly when the ANA is positive at a low level. Specificity of testing can be increased by testing for specific antibodies against individual nuclear antigens (extractable nuclear antigens) to examine the “pattern” of ANA positivity. These include antigens against single- and dsDNA, histones, Sm, Ro, La, and RNP antibodies. The presence of anti-dsDNA or anti-Sm is highly specific for SLE because few patients without SLE test positive; however, neither test has high sensitivity. The presence of other antibody patterns may indicate the likelihood of other diagnoses; eg, the presence of Ro and La antibodies suggests Sjögren syndrome, while the presence of antihistone antibodies suggests drug-induced lupus.

Better diagnostic tests for SLE and other CTDs would be useful in clinical practice. A variety of biomarkers, including markers associated with the complement system, are being explored to aid in the diagnosis of lupus. The complement system is part of the immune system and consists of 20 to 30 protein molecules that circulate in the blood in an inactive form until activated by a trigger (eg, an infection)—and when the protein molecules are activated, a sequence of events known as the complement cascade is initiated. This cascade involves the proteolysis of a complement protein into a smaller protein and a peptide. The smaller protein is able to bind to the complex one at the surface of the invading microorganism, and the peptide diffuses away. For example, in the first step, complement protein C3 is cleaved into C3b and C3a. C3b binds to the surface of the microorganism and activates the next step in the cascade, the proteolysis of C5, and the small peptide, C3a diffuses away. The precursors C3 and C4 and the complement activation products (eg, C3a, C5a, C4d) have been considered as SLE biomarkers. More recently, cell-bound complement activation products, which live longer than circulating complement activation products, have been investigated as biomarkers of SLE.

In addition to exploration of individual biomarkers with higher accuracy than accepted markers (eg, ANA, anti-dsDNA), there is interest in identifying a panel of tests with high sensitivity and specificity for SLE diagnosis. At least 1 multibiomarker test to aid diagnosis of SLE and other CTDs is commercially available. This panel, Avise CTD (Exagen Diagnostics), contains 22 different tests. It combines 2 smaller panels, a 10-marker panel that includes common SLE tests, as well as cell-bound complement activation products (known as Avise Lupus) and a 12-marker panel that focuses on CTDs other than SLE (known as Avise CTD). Avise CTD includes nuclear antigen antibodies markers to help distinguish CTD, a rheumatoid arthritis panel to rule-in or rule-out rheumatoid arthritis, an antiphospholipid syndrome panel to assess risk for thrombosis and cardiovascular events, and a thyroid panel to help rule-in or rule-out Graves disease and Hashimoto disease. Specific biomarkers in the panel are listed in Table 2.

<table>
<thead>
<tr>
<th>Table 2. Avise Systemic Lupus Erythematosus Tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systemic Lupus Erythematosus Tests</td>
</tr>
<tr>
<td>10-marker Avise Lupus test</td>
</tr>
<tr>
<td>o Auto-antibodies: ANA, anti-dsDNA, antimutated citrullinated vimentin, C4d erythrocyte-bound complement</td>
</tr>
<tr>
<td>o fragment, C4d lymphocyte-bound complement, anti-Sm, Jo-1, Sci-70, CENP, SS-B/La</td>
</tr>
<tr>
<td>Avise CTD test</td>
</tr>
</tbody>
</table>


Avise Lupus test plus the following:
- Auto-antibodies: U1RNP, RNP70, SS-A/Ro
- Rheumatoid arthritis auto-antibodies: rheumatoid factor IgM, rheumatoid factor IgA, anticyclic citrullinated peptide
- IgG
- Anti-phospholipid syndrome auto-antibodies: cardiolipin IgM, cardiolipin IgG, β2-glycoprotein 1 IgG, β2-glycoprotein 1 IgM
- Thyroid auto-antibodies: thyroglobulin IgG, thyroid, thyroid peroxidase

ANA: antinuclear antibody; anti-dsDNA: antibodies to double-stranded DNA; anti-Sm: antibodies to Smith nuclear antigen; Ig: immunoglobulin.

All 22 markers are assessed when the Avise CTD test is ordered. Avise CTD uses a 3-step process. The 10-marker panel is done in 2 tiers, and the add-on 12-marker panel is done in a third step to further assist with the differential diagnosis of CTD. In addition, ANA testing is done by enzyme-linked immunosorbent assay and by indirect immunofluorescence. The 2-tiered testing approach to the 10-marker panel is described next.

**Tier 1:** Tests for anti-Sm, EC4d, BC4d, and anti-dsDNA. If any tests are positive, the result is considered suggestive of SLE and no further testing is done. Cutoffs for positivity are greater than 10 U/mL for anti-Sm, greater than 75 U/mL for EC4d, greater than 200 U/mL for BC4d, and greater than 301 U/mL for anti-dsDNA. Positive findings for anti-dsDNA are confirmed with a *Crithidia luciliae* assay.

**Tier 2:** If the tier 1 tests are negative, an index score is created, consisting of results of tests for ANA, EC4d and BC4d, antimutated citrullinated vimentin, anti-Jo-1, anti-Sci-70, anti-CENP, and anti-Ss-B/La. In other words, there are 6 additional markers and the ratio of EC4d to BC4d, both of which were measured in tier 1.)

The index score, calculated using a proprietary algorithm, rates how suggestive test results are of SLE. Although there is information on cutoffs used to indicate positivity for individual markers, information is not available on how precisely the index score is calculated. The score can range from -5 (highly nonsuggestive of SLE) to 5 (highly suggestive of SLE), and a score of -0.1 to 0.1 is considered indeterminate.

Exagen also offers the Avise Lupus Prognostic test, a 10-marker panel that can be ordered with the Avise Lupus/Avise CTD panels. The prognostic test focuses on patients’ risk of lupus nephritis, neuropsychiatric SLE, thrombosis, and cardiovascular events. The test includes anti-C1q, anti-ribosomal P, antiphosphatidylserine/prothrombin immunoglobulin (Ig) M and IgG, anti-cardiolipin IgM, IgG, and IgA and anti-β2-glycoprotein 1 IgM, IgG, and IgA. Four of the 10 markers are included in both panel tests.

**Treatment**
Treatments for SLE can ameliorate symptoms, reduce disease activity, and slow progression of organ damage; however, there is no cure for SLE. Muscle and joint pain, fatigue, and rashes are generally treated initially with nonsteroidal anti-inflammatory drugs. Antimalarial drugs such as hydroxychloroquine can relieve some symptoms of SLE including fatigue, rashes, and joint pain. Patients with more severe symptoms (eg, heart, lung, or kidney involvement) can be treated with corticosteroids or immune suppressants. There are also biologic treatments (eg, rituximab) approved by the U.S. Food and Drug Administration for treatment of rheumatoid arthritis and are being evaluated for SLE.

**Summary**
For individuals with signs and/or symptoms of SLE who receive serum biomarker panel testing, the evidence includes several diagnostic accuracy studies. Relevant outcomes are test accuracy, symptoms, and quality of life. One study evaluated a panel similar to a commercially available test; it found that the panel test had somewhat higher specificity and lower sensitivity than the most common currently used biomarkers. The clinical significance of this degree of difference in diagnostic accuracy is
unclear. One case-control study found a high sensitivity and specificity for a commercially available test for diagnosing SLE, but this retrospective analysis has several limitations, and prospective studies are therefore needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals with signs and/or symptoms of CTD (besides SLE) who receive serum biomarker panel testing, more studies are needed. Relevant outcomes are test accuracy, symptoms, and quality of life. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Policy History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>9/2017</td>
<td>BCBSA National medical policy review. The phrase “and other connective tissue diseases” added to policy statement and title. 9/1/2017</td>
</tr>
<tr>
<td>11/2015</td>
<td>New references added from BCBSA National medical policy.</td>
</tr>
</tbody>
</table>

**Information Pertaining to All Blue Cross Blue Shield Medical Policies**

Click on any of the following terms to access the relevant information:

- Medical Policy Terms of Use
- Managed Care Guidelines
- Indemnity/PPO Guidelines
- Clinical Exception Process
- Medical Technology Assessment Guidelines

**References**


